Researchers report on the feasibility of TFR in patients with CML-CP in updated analysis of the ENESTfreedom study.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.